Loading…
Advances in the treatment of cytomegalovirus
Human cytomegalovirus (HCMV) is a threat to immunologically weak patients. HCMV cannot yet be eliminated with a vaccine, despite recent advances. Sources of data are recently published research papers and reviews about HCMV treatments. Current antivirals target the UL54 DNA polymerase and are limite...
Saved in:
| Published in: | British medical bulletin 2019-09, Vol.131 (1), p.5-17 |
|---|---|
| Main Authors: | , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c378t-e369c44226d3ad9b9ae356034bdd606d2cde391a9ac2bc0bf023998efb0773c93 |
|---|---|
| cites | cdi_FETCH-LOGICAL-c378t-e369c44226d3ad9b9ae356034bdd606d2cde391a9ac2bc0bf023998efb0773c93 |
| container_end_page | 17 |
| container_issue | 1 |
| container_start_page | 5 |
| container_title | British medical bulletin |
| container_volume | 131 |
| creator | Krishna, B A Wills, M R Sinclair, J H |
| description | Human cytomegalovirus (HCMV) is a threat to immunologically weak patients. HCMV cannot yet be eliminated with a vaccine, despite recent advances.
Sources of data are recently published research papers and reviews about HCMV treatments.
Current antivirals target the UL54 DNA polymerase and are limited by nephrotoxicity and viral resistance. Promisingly, letermovir targets the HCMV terminase complex and has been recently approved by the FDA and EMA.
Should we screen newborns for HCMV, and use antivirals to treat sensorineural hearing loss after congenital HCMV infection?
Growing points are developing drugs against latently infected cells. In addition to small molecule inhibitors, a chemokine-based fusion toxin protein, F49A-FTP, has shown promise in killing both lytically and latently infected cells.
We need to understand what immune responses are required to control HCMV, and how best to raise these immune responses with a vaccine. |
| doi_str_mv | 10.1093/bmb/ldz031 |
| format | article |
| fullrecord | <record><control><sourceid>pubmed_cross</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6821982</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>31580403</sourcerecordid><originalsourceid>FETCH-LOGICAL-c378t-e369c44226d3ad9b9ae356034bdd606d2cde391a9ac2bc0bf023998efb0773c93</originalsourceid><addsrcrecordid>eNpVkE1Lw0AQhhdRbKxe_AGSsxg7u5MmuxehFL-g4EXPy36ljeSj7KaB-usbiRY9zWHeeeblIeSawj0FgTNd61llvwDpCYlomtOEo6CnJAKAPKEpgwm5COETgCICPycTpHMOKWBE7ha2V41xIS6buNu4uPNOdbVrurgtYrPv2tqtVdX2pd-FS3JWqCq4q585JR9Pj-_Ll2T19vy6XKwSgznvEoeZMGnKWGZRWaGFcjjPAFNtbQaZZca6oaASyjBtQBfAUAjuCg15jkbglDyM3O1O186aoY1Xldz6slZ-L1tVyv-bptzIddvLjDMqOBsAtyPA-DYE74rjLQX57UwOzuTobAjf_P12jP5KwgPX32nC</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Advances in the treatment of cytomegalovirus</title><source>Oxford Journals Online</source><creator>Krishna, B A ; Wills, M R ; Sinclair, J H</creator><creatorcontrib>Krishna, B A ; Wills, M R ; Sinclair, J H</creatorcontrib><description>Human cytomegalovirus (HCMV) is a threat to immunologically weak patients. HCMV cannot yet be eliminated with a vaccine, despite recent advances.
Sources of data are recently published research papers and reviews about HCMV treatments.
Current antivirals target the UL54 DNA polymerase and are limited by nephrotoxicity and viral resistance. Promisingly, letermovir targets the HCMV terminase complex and has been recently approved by the FDA and EMA.
Should we screen newborns for HCMV, and use antivirals to treat sensorineural hearing loss after congenital HCMV infection?
Growing points are developing drugs against latently infected cells. In addition to small molecule inhibitors, a chemokine-based fusion toxin protein, F49A-FTP, has shown promise in killing both lytically and latently infected cells.
We need to understand what immune responses are required to control HCMV, and how best to raise these immune responses with a vaccine.</description><identifier>ISSN: 0007-1420</identifier><identifier>EISSN: 1471-8391</identifier><identifier>DOI: 10.1093/bmb/ldz031</identifier><identifier>PMID: 31580403</identifier><language>eng</language><publisher>England: Oxford University Press</publisher><subject>Antiviral Agents - pharmacology ; Antiviral Agents - therapeutic use ; Cytomegalovirus - physiology ; Cytomegalovirus Infections - congenital ; Cytomegalovirus Infections - immunology ; Cytomegalovirus Infections - prevention & control ; Cytomegalovirus Vaccines ; Drug Development ; Early Diagnosis ; Hematopoietic Stem Cell Transplantation - adverse effects ; Humans ; Immunity, Cellular - physiology ; Immunoglobulins - therapeutic use ; Immunosuppression - adverse effects ; Infant, Newborn ; Invited Review ; Organ Transplantation - adverse effects ; Perinatal Care ; Virus Latency - drug effects</subject><ispartof>British medical bulletin, 2019-09, Vol.131 (1), p.5-17</ispartof><rights>The Author(s) 2019. Published by Oxford University Press.</rights><rights>The Author(s) 2019. Published by Oxford University Press. 2019</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c378t-e369c44226d3ad9b9ae356034bdd606d2cde391a9ac2bc0bf023998efb0773c93</citedby><cites>FETCH-LOGICAL-c378t-e369c44226d3ad9b9ae356034bdd606d2cde391a9ac2bc0bf023998efb0773c93</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,780,784,885,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/31580403$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Krishna, B A</creatorcontrib><creatorcontrib>Wills, M R</creatorcontrib><creatorcontrib>Sinclair, J H</creatorcontrib><title>Advances in the treatment of cytomegalovirus</title><title>British medical bulletin</title><addtitle>Br Med Bull</addtitle><description>Human cytomegalovirus (HCMV) is a threat to immunologically weak patients. HCMV cannot yet be eliminated with a vaccine, despite recent advances.
Sources of data are recently published research papers and reviews about HCMV treatments.
Current antivirals target the UL54 DNA polymerase and are limited by nephrotoxicity and viral resistance. Promisingly, letermovir targets the HCMV terminase complex and has been recently approved by the FDA and EMA.
Should we screen newborns for HCMV, and use antivirals to treat sensorineural hearing loss after congenital HCMV infection?
Growing points are developing drugs against latently infected cells. In addition to small molecule inhibitors, a chemokine-based fusion toxin protein, F49A-FTP, has shown promise in killing both lytically and latently infected cells.
We need to understand what immune responses are required to control HCMV, and how best to raise these immune responses with a vaccine.</description><subject>Antiviral Agents - pharmacology</subject><subject>Antiviral Agents - therapeutic use</subject><subject>Cytomegalovirus - physiology</subject><subject>Cytomegalovirus Infections - congenital</subject><subject>Cytomegalovirus Infections - immunology</subject><subject>Cytomegalovirus Infections - prevention & control</subject><subject>Cytomegalovirus Vaccines</subject><subject>Drug Development</subject><subject>Early Diagnosis</subject><subject>Hematopoietic Stem Cell Transplantation - adverse effects</subject><subject>Humans</subject><subject>Immunity, Cellular - physiology</subject><subject>Immunoglobulins - therapeutic use</subject><subject>Immunosuppression - adverse effects</subject><subject>Infant, Newborn</subject><subject>Invited Review</subject><subject>Organ Transplantation - adverse effects</subject><subject>Perinatal Care</subject><subject>Virus Latency - drug effects</subject><issn>0007-1420</issn><issn>1471-8391</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><recordid>eNpVkE1Lw0AQhhdRbKxe_AGSsxg7u5MmuxehFL-g4EXPy36ljeSj7KaB-usbiRY9zWHeeeblIeSawj0FgTNd61llvwDpCYlomtOEo6CnJAKAPKEpgwm5COETgCICPycTpHMOKWBE7ha2V41xIS6buNu4uPNOdbVrurgtYrPv2tqtVdX2pd-FS3JWqCq4q585JR9Pj-_Ll2T19vy6XKwSgznvEoeZMGnKWGZRWaGFcjjPAFNtbQaZZca6oaASyjBtQBfAUAjuCg15jkbglDyM3O1O186aoY1Xldz6slZ-L1tVyv-bptzIddvLjDMqOBsAtyPA-DYE74rjLQX57UwOzuTobAjf_P12jP5KwgPX32nC</recordid><startdate>20190919</startdate><enddate>20190919</enddate><creator>Krishna, B A</creator><creator>Wills, M R</creator><creator>Sinclair, J H</creator><general>Oxford University Press</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>5PM</scope></search><sort><creationdate>20190919</creationdate><title>Advances in the treatment of cytomegalovirus</title><author>Krishna, B A ; Wills, M R ; Sinclair, J H</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c378t-e369c44226d3ad9b9ae356034bdd606d2cde391a9ac2bc0bf023998efb0773c93</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Antiviral Agents - pharmacology</topic><topic>Antiviral Agents - therapeutic use</topic><topic>Cytomegalovirus - physiology</topic><topic>Cytomegalovirus Infections - congenital</topic><topic>Cytomegalovirus Infections - immunology</topic><topic>Cytomegalovirus Infections - prevention & control</topic><topic>Cytomegalovirus Vaccines</topic><topic>Drug Development</topic><topic>Early Diagnosis</topic><topic>Hematopoietic Stem Cell Transplantation - adverse effects</topic><topic>Humans</topic><topic>Immunity, Cellular - physiology</topic><topic>Immunoglobulins - therapeutic use</topic><topic>Immunosuppression - adverse effects</topic><topic>Infant, Newborn</topic><topic>Invited Review</topic><topic>Organ Transplantation - adverse effects</topic><topic>Perinatal Care</topic><topic>Virus Latency - drug effects</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Krishna, B A</creatorcontrib><creatorcontrib>Wills, M R</creatorcontrib><creatorcontrib>Sinclair, J H</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>British medical bulletin</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Krishna, B A</au><au>Wills, M R</au><au>Sinclair, J H</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Advances in the treatment of cytomegalovirus</atitle><jtitle>British medical bulletin</jtitle><addtitle>Br Med Bull</addtitle><date>2019-09-19</date><risdate>2019</risdate><volume>131</volume><issue>1</issue><spage>5</spage><epage>17</epage><pages>5-17</pages><issn>0007-1420</issn><eissn>1471-8391</eissn><abstract>Human cytomegalovirus (HCMV) is a threat to immunologically weak patients. HCMV cannot yet be eliminated with a vaccine, despite recent advances.
Sources of data are recently published research papers and reviews about HCMV treatments.
Current antivirals target the UL54 DNA polymerase and are limited by nephrotoxicity and viral resistance. Promisingly, letermovir targets the HCMV terminase complex and has been recently approved by the FDA and EMA.
Should we screen newborns for HCMV, and use antivirals to treat sensorineural hearing loss after congenital HCMV infection?
Growing points are developing drugs against latently infected cells. In addition to small molecule inhibitors, a chemokine-based fusion toxin protein, F49A-FTP, has shown promise in killing both lytically and latently infected cells.
We need to understand what immune responses are required to control HCMV, and how best to raise these immune responses with a vaccine.</abstract><cop>England</cop><pub>Oxford University Press</pub><pmid>31580403</pmid><doi>10.1093/bmb/ldz031</doi><tpages>13</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0007-1420 |
| ispartof | British medical bulletin, 2019-09, Vol.131 (1), p.5-17 |
| issn | 0007-1420 1471-8391 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6821982 |
| source | Oxford Journals Online |
| subjects | Antiviral Agents - pharmacology Antiviral Agents - therapeutic use Cytomegalovirus - physiology Cytomegalovirus Infections - congenital Cytomegalovirus Infections - immunology Cytomegalovirus Infections - prevention & control Cytomegalovirus Vaccines Drug Development Early Diagnosis Hematopoietic Stem Cell Transplantation - adverse effects Humans Immunity, Cellular - physiology Immunoglobulins - therapeutic use Immunosuppression - adverse effects Infant, Newborn Invited Review Organ Transplantation - adverse effects Perinatal Care Virus Latency - drug effects |
| title | Advances in the treatment of cytomegalovirus |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-07T21%3A15%3A29IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Advances%20in%20the%20treatment%20of%20cytomegalovirus&rft.jtitle=British%20medical%20bulletin&rft.au=Krishna,%20B%20A&rft.date=2019-09-19&rft.volume=131&rft.issue=1&rft.spage=5&rft.epage=17&rft.pages=5-17&rft.issn=0007-1420&rft.eissn=1471-8391&rft_id=info:doi/10.1093/bmb/ldz031&rft_dat=%3Cpubmed_cross%3E31580403%3C/pubmed_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c378t-e369c44226d3ad9b9ae356034bdd606d2cde391a9ac2bc0bf023998efb0773c93%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_id=info:pmid/31580403&rfr_iscdi=true |